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INTRODUCTION
It is widely accepted that endothelial dysfunction precedes
and may cause diabetic microangiopathy in type 1 diabetes
mellitus (DM) receiving standard insulin therapy (1, 2). How-
ever, no clinical studies have been reported, to confirm the rela-
tionship between the functional studies of vascular endothe-
lium and the presence of microangiopathy. In the present study,
we examined whether alterations in vascular endothelial func-
tion and early structural changes in atherosclerosis are associ-
ated with the presence of the microvascular complications in
young adults with type 1 DM.
MATERIALS AND METHODS
Study populations
The study population consisted of 48 young adults with type
1 DM, all of whom were diabetic for at least 6 yr and were tak-
ing insulin. There were 25 males and 23 females (mean age,
24.8±3.6 yr [range, 20 to 33.5 yr]). The duration of their dia-
betes was 13.8±4.3 yr (range, 6.8 to 24.8 yr). Twenty two age-
and gender-matched subjects (age 23.8±5.4 yr [range 19 to
35 yr]; 12 males and 10 females) were recruited for the healthy
control subjects after informed consent. We excluded subjects
with arterial hypertension, hyperglycemia, hyperlipidemia,
microalbuminuria, obesity (body mass index >25 kg/m2), a
history of smoking or significant passive exposure to smoking,
a family history of premature vascular disease, and those tak-
ing any medication. Ten of the diabetic, patients were medi-
cated with angiotensin-converting enzyme inhibitors (ACEi)
for more than 3 months. ACEi were medicated for the purpose
of renal protection and afterload reduction in the patients who
had diabetic nephropathy with or without systemic arterial
hypertension.
Study design
At the outpatient clinic, a physical examination was per-
formed, and blood samples were obtained by venipuncture in
the morning after 8 to 12 hr of fasting. The serum levels of
creatinine, glycosylated hemoglobin (HbA1C), C-reactive pro-
tein (CRP), total cholesterol, low-density lipoprotein (LDL)-
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Endothelial Dysfunction and Microvascular Complications in Type 1
Diabetes Mellitus
We examined whether alterations in vascular endothelial function and early struc-
tural changes in atherosclerosis are associated with microvascular complications
in patients with type 1 diabetes mellitus (DM). Flow-mediated dilation (FMD) of the
brachial artery and carotid intima-media thickness (IMT) measurement were per-
formed in 70 young adults (aged 19 to 35 yr), 48 with type 1 DM, and 22 normal
controls. Patients with diabetes had a lower peak FMD response (7.8±3.9 vs. 11.1
±1.9%, p<0.001) and increased IMT (0.51±0.10 vs. 0.42±0.07 mm, p<0.001)
compared with controls. Twenty (41.7%) of the patients had microvascular com-
plications including neuropathy, nephropathy, or retinopathy. In these complicated
diabetic patients, we found a lower FMD response (6.1±2.5 vs. 9.9±3.5%, p=0.001)
compared with diabetics without microvascular complications. The presence of mi-
crovascular complications was also associated with older age and longer duration of
the disease. However, no differences were observed in IMT, body size, blood pres-
sure, HbA1c, C-reactive protein, low-density lipoprotein or high-density lipoprotein
cholesterol levels between complicated and non-complicated patients. Endothelial
dysfunction and early structural atherosclerotic changes are common manifestations
in type 1 DM, and endothelial dysfunction is thought to be an early event in the
atherosclerotic process and important in the pathogenesis of microvascular com-
plications.
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cholesterol, and high-density lipoprotein (HDL)-cholesterol
were checked. All type 1 diabetic patients were assessed for
subclinical evidence of microvascular complications and abnor-
mal neurologic function. To evaluate the presence of nephropa-
thy, albuminuria was assessed on 24 hr of urine collection. Mi-
croalbuminuria was defined as 30-300 mg/24 hr or 20-200 g/
min in 2 out of 3 consecutive tests taken within 2-3 months.
The glomerular filtration rate was estimated from the levels
of serum and urine creatinine (3, 4). The presence of retinopa-
thy was assessed by fundus photography, which was interpret-
ed by ophthalmologists. Peripheral nerve function was assessed
by the measurement of nerve conduction velocity (NCV) (4, 5).
The vascular study was performed between 11 AM to 2
PM with the usual morning dose of insulin for diabetic sub-
jects and a light, low-fat breakfast for which subjects received
specific instructions. For the flow-mediated vasodilation (FMD)
of the brachial artery, patients fasted for ≥4 hr before the study.
ACEi were discontinued for at least four times of the expect-
ed half life of captopril or enalapril in each diabetic patient.
Caffein intake and cigarette smoking were prohibited for 24
hr before the study.
After arrival, the subjects rested in a quiet, temperature-con-
trolled room for 15 min in the supine position, and then con-
ventional transthoracic echocardiogram was performed before
the procedure of vascular function test. Quantitative analysis
in the form of two-dimensional (2D) and Doppler echocardio-
graphy was performed to determine ventricular function, aor-
tic insufficiency, and atrioventricular valve regurgitation. We
excluded patients with moderate to severe ventricular dysfunc-
tion, aortic insufficiency, or atrioventricular valve regurgitation.
The study protocol was approved by the Ethics Commit-
tee of Seoul National University (Seoul, Korea), and informed
consent was obtained before the study from all patients and/or
their parents after a detailed description of the procedure.
FMD and intima media thickness (IMT) 
All studies were performed with a Vivid 7 ultrasound ma-
chine (GE-Vingmed, Horten, Norway) using 12-MHz lin-
ear array transducer. FMD of the brachial artery was assessed
according to the standard protocols (6). After recording base-
line image and Doppler signal, a blood pressure cuff was placed
at the distal forearm and inflated to supra-systolic pressure
(180-200 mmHg) for 5 min. Then the cuff was rapidly deflat-
ed and Doppler signal was recorded for 15 sec. The vessel was
continuously scanned from baseline until 3 min after cuff defla-
tion. Digital loops were stored on the hard disk of the echocar-
diography machine, and transferred to a workstation (EchoPAC
PC, General Electric, Horten, Norway) for offline analysis.
The brachial artery diameter was determined in end diastole,
indicated by the R wave of the electrocardiogram. Reactive
hyperemia (RH) was calculated as the percentage change in
blood flow from baseline. Blood flow (F) was calculated from
mean velocity of blood (V) and vessel diameters (D) during bas-
eline (V1, D1) and maximal reactive hyperemic period (V2, D2)
as follows: RH (%)=100(F2-F1)/F1=100 (V2× D22-V1× D12)/
V1× D12.
Maximal obtained diameter during ischemia-induced hyper-
emia was used for the calculation of FMD. FMD was expressed
as percent changes in the diameter ([maximum diameter-base-
line diameter]/baseline diameter×100%).
Carotid IMT was measured at common carotid artery, 10
mm proximal to the bifurcation. The far wall IMT was iden-
tified as the region between the lumen- intima interface and the
media-adventitia interface (7). Imaging was performed by two
experienced sonographers who were blinded to the clinical or
laboratory profile of the study patient. Offline measurements
were taken by two physicians who also had no knowledge of
the clinical or laboratory profile of the study subjects. Data
from at least 3 measurements were averaged for the calcula-
tion of FMD and IMT. The intra- and inter-observer variabil-
ity expressed as coefficients of variation were 6.8 and 7.1%
for FMD, and 5.4 and 5.8% for IMT, respectively. The results
of the measurements of FMD and IMT were highly repro-
ducible.
Statistical analysis
All data were stored and analyzed using the SPSS statisti-
cal package 12.0 (SPSS Inc., Chicago, IL, U.S.A.). Descriptive
data are expressed as mean±standard deviation (SD). For the
comparison of quantitative data of the 2 groups, the Student s
t test or chi-square test was applied. A p value less than 0.05
was considered statistically significant. 
RESULTS
The clinical characteristics of the type 1 diabetic patients
and controls are given in Table 1. There were no significant
differences in age, gender distribution, body weight, height,
body mass index, and diastolic blood pressure between the
groups. However, mean systolic blood pressure was signifi-
cantly higher in diabetic patients. Twelve (25%) of the dia-
betic patients had systemic hypertension.
The results of ultrasound studies are shown in Table 1. There
were no significant differences between the two groups in br-
achial artery baseline diameter or increase in blood flow dur-
ing reactive hyperemia. Patients with type 1 DM had lower
peak FMD response (7.8±3.9 vs. 11.1±1.9%, p<0.001) and
increased IMT (0.51±0.10 vs. 0.42±0.07 mm, p<0.001)
compared with controls. Thirty-six diabetic patients without
hypertension also showed reduced FMD (7.2±3.2 vs. 11.1
±1.9%, p<0.001) and increased IMT (0.51±0.11 vs. 0.42
±0.07 mm, p=0.001) compared with controls.
Twenty (41.7%) of the patients had one or more microvas-
cular complications including neuropathy, nephropathy, or
retinopathy. Thirteen patients had nephropathy, eight patients
78 S.M. Jin, C.I. Noh, S.W. Yang, et al.
had retinopathy, and two patients had neuropathy. Two of the
patients who had diabetic nephropathy also had retinopathy
concomitantly. In these complicated diabetic patients, we found
lower FMD response compared with diabetics without micro-
vascular complications (6.1±2.5 vs. 9.9±3.5%, p=0.001)
(Table 2). The presence of microvascular complications was
also associated with older age and longer duration of the dis-
ease. However, no differences were observed in IMT, body size,
systolic or diastolic blood pressure, HbA1c, CRP, LDL or HDL
cholesterol levels between complicated and non-complicated
patients.
Non-complicated diabetic patients showed significantly
lower FMD (9.9±3.5 vs. 11.1±1.9%, p=0.001) and higher
IMT (0.51±0.09 vs. 0.42±0.07 mm, p=0.013) compared
with controls. Fig. 1 shows the peak FMD values across 3 gro-
ups (controls and diabetic patients with and without microvas-
cular complications).
DISCUSSION
Morbidity and mortality in diabetes mellitus are caused ch-
iefly by its vascular complications, both in the microcircula-
tion and in large vessels. Microangiopathy of the vasa nervo-
rum is important in the pathogenesis of diabetic neuropathy,
and diabetic retinopathy and nephropathy are the hallmarks
of microangiopathy. Diabetic nephropathy is strongly associ-
ated with other complications, including neuropathy, retinopa-
thy, and atherosclerosis (8). Considerable laboratory and clini-
cal evidence indicates that endothelial dysfunction is a critical
part of the pathogenesis of microvascular and macrovascular
complications in type 1 DM (9-11). However, the literature
on endothelial function in diabetes is complex in part because
endothelial function can be measured in many ways and in
many vascular beds (1). 
The FMD, endothelium-dependent vasodilation during re-
active hyperemia, is predominantly modulated by local release
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Data are presented as the mean value±SD.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HbA1c, glycosylated hemoglobin; D1, baseline brachial artery
diameter; RH, reactive hyperemia; FMD, flow-mediated vasodilation; IMT,
intima-media thickness.
Controls Diabetic patients p value
Number of subjects (male) 22 (12) 48 (25) -
Age (range), yr 23.8±5.4 24.8±3.6 0.375
(19-35) (20-33.5)
Disease duration - 13.8±4.3 -
(range), yr (6.8-24.8)
Height (m) 1.70±0.07 1.65±0.08 0.129
Weight (kg) 63.7±10.9 60.0±8.8 0.148
BMI (kg/m2) 21.7±2.9 21.9±2.2 0.765
SBP (mmHg) 121±12 125±11 0.04
DBP (mmHg) 76±10 76±8 0.884
HbA1c (%) - 8.5±1.5 -
D1 (mm) 3.57±0.49 3.41±0.43 0.196
RH (%) 258±146 251±131 0.866
FMD (%) 11.1±1.9 7.8±3.9 <0.001
IMT (mm) 0.42±0.07 0.51±0.10 <0.001
Table 1. Clinical characteristics and results of the ultrasound stud-
ies in controls and type 1 diabetic patients
Data are presented as the mean value±SD.
w/o, without; w, with; CRP, C-reactive protein; HDL and LDL, high- and
low-density lipoprotein; other abbreviations are same as in Table 1.
Diabetic group 1 Diabetic group 2
(w/o complica- (w complica- p value
tions) tions)
Number of subjects (male) 28 (15) 20 (10) -
Age (range), yr 23.5±2.5 26.5±4.1 0.007
(20-29) (21-34)
Disease duration (range), yr 12.3±3.7 15.9±4.3 0.004
(6.8-24.6) (9.5-24.8)
Height (m) 1.66±0.07 1.63±0.09 0.253
Weight (kg) 60.0±8.4 60.1±9.5 0.956
BMI (kg/m2) 21.5±1.7 22.3±2.7 0.216
SBP (mmHg) 124.6±10.4 126.8±11.8 0.588
DBP (mmHg) 75.6±6.9 77.5±9.4 0.490
Insulin dose (unit) 44.9±10.9 46.5±11.1 0.659
HbA1c (%) 8.2±1.5 8.9±1.5 0.189
CRP (mg/dL) 0.08±0.09 0.11±0.15 0.325
Total cholesterol (mg/dL) 173.6±40.7 192.2±43.0 0.098
LDL cholesterol (mg/dL) 97.3±33.5 102.3±21.7 0.509
HDL cholesterol (mg/dL) 65.2±12.8 66.7±16.5 0.597
D1 (mm) 3.42±0.45 3.38±0.41 0.815
RH (%) 245±115 263±158 0.682
FMD (%) 9.9±3.5 6.1±2.5 0.001
IMT (mm) 0.51±0.10 0.52±0.11 0.719
Table 2. Clinical characteristics and results of the laboratory and
ultrasound studies in non-complicated (diabetic group 1) and
complicated (diabetic group 2) type 1 diabetic patients
Fig. 1. Comparison of the results of flow-mediated vasodilation (FMD)
in three study groups (controls, non-complicated and complicated



















of nitric oxide (12). Impaired local availability of nitric oxide
and endothelium-dependent vasodilation may result from either
short- or long-term exposure to several factors. With recurrent
or persistent exposure to the risk factors, there is a state of per-
sistent endothelial dysfunction and altered vascular wall milieu
that promotes structural changes of atherosclerosis (13). In the
present study, the patients with type 1 DM had lower peak
FMD response and increased IMT compared with controls.
Several studies have reported that endothelial dysfunction is
common in children and young adults with type 1 DM of short
duration (5, 13-15). Endothelial dysfunction in large arteries
is paralleled by endothelial dysfunction in resistance vessels
and metabolically important capillary beds that contributes
to the development of the metabolic syndrome (16). Impaired
FMD response is associated with increased carotid artery IMT.
Endothelial dysfunction in children with type 1 DM may pre-
dispose them to the development of early atherosclerosis (14).
Increased IMT is believed to represent structural atheroscle-
rosis and is a proven risk factor for myocardial infarction and
stroke in older adults (17). Our result is consistent with the
previous study (18), which found a significant, albeit small,
increase in carotid IMT in diabetic children compared with
control subjects.
The mean FMD values in controls and diabetic patients in
the present study were higher than those observed in the pre-
vious studies (14, 15). And the mean IMT values in controls
and diabetic patients in the present study were lower than those
observed in the previous study (14). Compared with the dia-
betic children of these former studies, those included in the
present study were older, had a longer duration of diabetes,
and many (41%) of the patients had diabetic microvascular
complications. Significant differences in genetic and environ-
mental cardiovascular risk factors (lifestyle, diet, or other risk
factors) between the study populations may explain the dis-
crepancy.
The mechanisms of endothelial dysfunction and accelerat-
ed atherosclerosis in diabetes are multifactorial and have not
been fully characterized. In this study, the glycemic control in
patients was suboptimal, with a mean glycosylated hemoglobin
value of 8.5±1.5% (range, 5.4 to 12%; normal value, 4.0 to
6.0% [19]). It is known that hyperglycaemia and its immedi-
ate biochemical sequelae directly alter endothelial function or
influence endothelial cell functioning indirectly by the synthe-
sis of growth factors, cytokines, and vasoactive agents in other
cells (1, 20, 21). In vitro, endothelial cells exposed to high glu-
cose show an increased production of extracellular matrix com-
ponents, such as collagen and fibronectin, and of procoagulant
proteins, such as von Willebrand factor and tissue factor, and
decreased proliferation, migration, and fibrinolytic potential
(22). Many of these features are also apparent in vivo, especially
in patients with micro- or macroalbuminuria (23). Glycosyl-
ation of LDL apolipoprotein B through nonenzymatic link-
ages and production of advanced glycation end products are
characteristic to diabetic hyperglycemia (24). Recent experi-
mental studies have shown glycated LDL to induce various
atherogenic events, including endothelial dysfunction (25).
The components of the metabolic syndrome can also affect
endothelial function in diabetes (26). Regardless of the pres-
ence of diabetes, chronic low-grade inflammation is closely
associated with endothelial dysfunction (27, 28).
In type I DM, patients who have had diabetes for more than
5-10 yr are characterized by subtle increases in blood pressure
and autonomic dysfunction (29). In this study, diabetic patients
showed higher systolic blood pressure than controls. Because
hypertension itself causes endothelial activation as indicated
by elevated levels of soluble adhesion molecules (30) and im-
paired NO availability (1), hypertension should be another
factor that resulted in endothelial dysfunction in diabetic pa-
tients. Hypertension is a confounding variable that can ren-
der the data interpretation problematic. Nevertheless, there
were 36 patients with type 1 DM without hypertension who
showed abnormal FMD and IMT.
In the present study, non-complicated diabetic patients show-
ed significantly lower FMD compared with controls. It is con-
sistent with the previous study, which reported that type 1
diabetic children without diabetic complications had atten-
uated endothelial function compared with controls (15). Dia-
betic patients with microvascular complications showed more
severely impaired FMD than diabetic patients without these
complications. NG-Monomethyl-L-arginine (an inhibitor of
endothelium-derived relaxing factor/nitric oxide biosynthesis)
did not influence nitroprusside (an endothelium-independent
vasodilator) responses but reduced carbachol (an endothelium-
dependent vasodilator) responses in control subjects and nor-
moalbuminuric diabetic patients but not in microalbuminuric
diabetic patients. These results provided evidence of abnormal
nitric oxide biosynthesis in insulin-dependent diabetic patients
with microalbuminuria (31). On the contrary, Donaghue et al.
reported that the changes in large vessel endothelial function
were not related to detectable microvascular disease or auto-
nomic dysfunction (5). Differences in the study populations
may explain this disparity. The subjects enrolled in the pre-
vious study (5) were younger, had a shorter duration of diabetes
compared to the present study. The small patient population
in the previous study may be insufficient to reveal the asso-
ciation between endothelial function and the presence of mi-
croangiopathy.
Endothelial dysfunction, as estimated by plasma vWF con-
centration, preceded the development of microalbuminuria in
type 1 DM (2). Other prospective studies have shown that high
vWF concentrations are associated with an increased risk of
developing microalbuminuria, an increased progression of mi-
croalbuminuria, the occurrence of diabetic retinopathy and
neuropathy and, an increased risk of cardiovascular events and
death (32-34). Endothelial dysfunction can contribute to the
pathogenesis of albuminuria both directly, by causing increased
glomerular pressure and the synthesis of a leaky glomerular
basement membrane, and indirectly, by influencing glomeru-
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lar mesangial and epithelial cell function in a paracrine fash-
ion (1). Chronic low-grade inflammation can be both the cause
and consequence of endothelial dysfunction, and it is one can-
didate to explain the association between (micro) albuminuria
and extrarenal complications (35, 36). Genetic or environmen-
tal factors are also likely to play a role in determining who am-
ong type 1 diabetic patients go on to develop aggressive ang-
iopathy and who do not (1).
The IMT measurements in diabetic patients were signifi-
cantly greater than those in the control population. However,
we found no differences in carotid IMT between complicat-
ed and non-complicated diabetic patients. In a recent study,
it was shown that abnormal FMD occurs within the first decade
of the disease in children with type 1 DM and precedes the
increase in IMT (13). Although endothelial dysfunction is not
atherosclerosis, it may be an important pathophysiological
precursor (37, 38). The increase in the carotid IMT would occur
after a considerably longer exposure to the diabetic milieu (13),
and it is the likely explanation for the findings in our study.
The relative timing of these events is important in the evalua-
tion of strategies to prevent progression of atherosclerosis and
other vascular complications in this patient population (13).
In conclusion, this study shows that young adults with type
1 DM have signs of large vascular endothelial dysfunction and
early atherosclerosis. Although the present study is a cross-sec-
tional study and only a small number of young adults were
investigated, our findings indicate that changes in systemic
vascular endothelial function predispose to microvascular com-
plications. Our results emphasize the importance of early detec-
tion and control of risk factors of endothelial dysfunction in
these patients. The assessment of FMD responses may provide
a valuable tool for risk stratification of the young patients with
type 1 DM.
Some limitations should be noted in this study. First, the
size of the patient population was small compared with that
of large studies of type 2 DM. Second, it was a cross-section-
al study that assessed the impairment of subclinical vascular
endothelial function and the presence of microangiopathy in
young adults with type 1 DM, so further longitudinal stud-
ies would be needed to clarify whether an improvement in
endothelial function would reduce the development of micro-
vascular complications in the young type 1 diabetic patients.
Third, although the patients with moderate to severe ventric-
ular dysfunction were excluded from this study, there must
be some interactions between ventricles and peripheral ves-
sels. The influences of ventricles on vessels were not analyzed
in the present study.
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